Chelation therapy for the management of diabetic complications: A hypothesis and a proposal for clinical laboratory assessment of metal ion homeostasis in plasma

Clinical Chemistry and Laboratory Medicine

Volumn 52, Issue 1, 2014, Pages 69-75

  Frizzell, Norma ^a   Baynes, John W ^a  

^a UNIVERSITY OF SOUTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

advanced glycation end product (AGE); AGE breaker; AGE inhibitor; autoxidation; chelation; chelation therapy; copper; diabetic complications; metal catalyzed oxidation; oxidative stress

Indexed keywords

CHELATING AGENT; COPPER; IRON;

ATHEROSCLEROSIS; AUTOOXIDATION; CHELATION THERAPY; CHRONIC DISEASE; CLINICAL LABORATORY; DEGENERATIVE DISEASE; DIABETES MELLITUS; HOMEOSTASIS; HUMAN; IN VIVO STUDY; LABORATORY TEST; PRIORITY JOURNAL; REVIEW;

CHELATING AGENTS; CHELATION THERAPY; COPPER; DIABETES COMPLICATIONS; GLYCOSYLATION END PRODUCTS, ADVANCED; HUMANS; HYDROGEN-ION CONCENTRATION; IONS; IRON; KINETICS; OXIDATION-REDUCTION; OXIDATIVE STRESS;

EID: 84879676494     PISSN: 14346621     EISSN: 14374331     Source Type: Journal    
DOI: 10.1515/cclm-2012-0881     Document Type: Review

References (60)

1. Goh SY, Cooper ME. The role of advanced glycation end-products in progression and complications of diabetes. J Clin Endocrinol Metab 2008;93:1143-52.
2. Negre-Salvayre A, Salvayre R, Auge N, Pamplona R, Portero-Otin M. Hyperglycemia and glycation in diabetic complications. Antiox Redox Signal 2009;11:3071-109.
3. Pamplona R, Naudí A, Gavín R, Pastrana MA, Sajnani G, Ilieva EV, et al. Increased oxidation, glycoxidation, and lipoxidation of brain proteins in prion disease. Free Radic Biol Med 2008;45:1159-66.
4. Pamplona R, Portero-Otín M, Requena J, Gredilla R, Barja G. Oxidative, glycoxidative and lipoxidative damage to rat heart mitochondrial proteins is lower after 4 months of caloric restriction than in age-matched controls. Mech Ageing Dev 2002;123:1437-46.
5. Ramaswamy R, Yan SF, Schmidt AM. The diverse ligand repertoire of the receptor for advanced glycation endproducts and pathways to the complications of diabetes. Vascul Pharmacol 2012;57:160-7.
6. Horiuchi S, Sakamoto Y, Sakai M. Scavenger receptors for oxidized and glycated proteins. Amino Acids 2003;25: 283-92.
7. Hodgkinson CP, Laxton RC, Patel K, Ye S. Advanced glycation end-product of low density lipoprotein activates the toll-like 4 receptor pathway: implications for diabetic atherosclerosis. Arterioscler Thromb Vasc Biol 2008;28:2275-81.
8. Onorato JM, Jenkins AJ, Thorpe SR, Baynes JW. Pyridoxamine, an inhibitor of advanced glycation reactions, also inhibits advanced lipoxidation reactions. Mechanism of action of pyridoxamine. J Biol Chem 2000;275:21177-84.
9. Chetrykin SV, Mathis ME, Ham AJ, Hachey DL, Hudson BG, Voziyan PA. Propagation of protein glycation damage involves modification of tryptophan residues by reactive oxygen species: inhibition by pyridoxamine. Free Radic Biol Med 2008; 44:1276-85.
10. Chetrykin S, Mathis M, Hayes McDonald W, Shackelford X, Hudson BG, Voziyan PA. Pyridoxamine protects protein backbone from oxidative fragmentation. Biochem Biophys Res Commun 2011;411:574-9.
11. Nagai R, Murray DB, Metz TO, Baynes JW. Chelation: A fundamental mechanism of action of AGE inhibitors, AGE breakers, and other inhibitors of diabetes complications. Diabetes 2012;61:549-59.
12. Rahbar S, Figarola JL. Inhibitors and breakers of advanced glycation endproducts (AGEs): A review. Curr Med Chem Immunol Endocr Metab Agents 2002;2:135-61.
13. Rahbar S, Figarola JL. Novel inhibitors of advanced glycation endproducts. Arch Biochem Biophys 2003;419:63-9.
14. Cooper GJ. Therapeutic potential of copper chelation with triethylenetetramine in managing diabetes mellitus and Alzheimer's disease. Drugs 2011;71:1281-320.
15. Cooper GJ. Selective divalent copper chelation for the treatment of diabetes mellitus. Curr Med Chem 2012;19:2828-60.
16. Stiles S. TACT: surprising, puzzling benefit from chelation therapy after MI. Available from: www.theheart.org. Accessed 4 November, 2012.
17. Logie L, Harthill J, Patel K, Bacon S, Hamilton DL, Macrae K, et al. Cellular responses to the metal-binding properties of metformin. Diabetes 2012;61:1423-33.
18. Brownlee M, Vlassara H, Kooney A, Ulrich P, Cerami A. Aminoguanidine prevents diabetes-induced arterial wall protein cross-linking. Science 1986;232:1629-32.
19. Vasan S, Zhang X, Zhang X, Kapurniotu A, Berhnagen J, Teichberg S, et al. An agent cleaving glucose-derived protein crosslinks in vitro and in vivo. Nature 1996;382:275-8.
20. Coughlan MT, Thallas-Bonke V, Pete J, Long DM, Gasser A, Tong DC, et al. Combination therapy with the advanced glycation end product cross-link breaker, alagebrium, and angiotensin converting enzyme inhibitors in diabetes: synergy or redundancy. Endocrinology 2007;148:886-95.
21. Sourris KC, Harcourt BE, Forbes JM. A new perspective on therapeutic inhibition of advanced glycation in diabetic microvascular complications: common downstream endpoints achieved through disparate therapeutic approaches. Am J Nephrol 2009;30:323-35.
22. Baynes JW, Murray DB. The metal chelators, trientine and citrate, inhibit the development of cardiac pathology in the Zucker diabetic rat. Exp Diab Res 2009;2009:696378.
23. Nagai R, Nagai M, Shimasaki S, Baynes JW, Fujiwara Y. Citric acid inhibits development of cataracts and ketosis in streptozotocin (type 1) diabetic rats. Biochem Biophys Res Commun 2010;393:118-22.
24. Wei H, Zhang WJ, McMillen TS, LeBoeuf RC, Frei B. Copper chelation by tetrathiomolybdate inhibits vascular inflammation and atherosclerotic lesion development in apolipoprotein E-deficient mice. Atherosclerosis 2012:223:306-13.
25. Sundararaman S, Vonseca VA, Alam MG, Shah SV. The role of iron in diabetes and its complications. Diabetes Care 2007;30:1926-33.
26. Rajpathak SN, Crandall JP, Wylie-Rosett J, Kabat GC, Rohan TE, Hu FB. The role of iron in type 2 diabetes in humans. Biochim Biophys Acta 2009;1790:671-81.
27. Stanley N, Stadler N, Woods AA, Bannon PG, Davies MJ. Concentrations of iron correlate with the extent of protein, but not lipid, oxidation in advanced human atherosclerotic lesions. Free Radic Biol Med 2006;40:1636-43.
28. Sullivan JL. Iron in arterial plaque: modifiable risk factor for atherosclerosis. Biochim Biophys Acta 2009;1790:718-23.
29. Smith MA, Harris PL, Sayre LM, Perry G. Iron accumulation in Alzheimer disease is a source of redox-generated free radicals. Proc Natl Acad Sci USA 1997;94:9866-8.
30. Castellani RJ, Moreira PI, Perry G, Zhu X. The role of iron as a mediator of oxidative stress in Alzheimer disease. Biofactors 2012;38:133-8.
31. Minqin R, Rajendran R, Pan N, Tan BK, Ong WY, Watt F, et al. The iron chelator desferrioxamine inhibits atherosclerotic lesion development and decreases lesion iron concentrations in the cholesterol-fed rabbit. Free Radic Biol Med 2005;32:1206-11.
32. Zhang WJ, Wei H, Frei B. The iron chelator, desferoxamine, reduces inflammation and atherosclerotic lesions in experimental mice. Exp Biol Med 2010;235:633-41.
33. Hider RC, Roy S, Ma YM, Le-Kong X, Preston J. The potential application of iron chelators for the treatment of neurodegenerative diseases. Metallomics 2011;3:239-49.
34. Li X, Jankovic J, Le W. Iron chelation and neuroprotection in neurodegenerative diseases. J Neural Transm 2011;118:473-7.
35. Budimir A. Metal ions, Alzheimer's disease and chelation therapy. Acta Pharm 2011;61:1-14.
36. Ayton S, Lei P, Bush AI. Metallostasis in Alzheimer disease. Free Radic Biol Med 2012 Nov 9. doi:pii: S0891-5849(12)01800-X [Epub ahead of print].
37. Brewer GJ. Copper toxicity in Alzheimer's disease: cognitive loss from ingestion of inorganic copper. J Trace Elem Med Biol 2012;26:89-92.
38. Brewer GJ. Metals in the causation and treatment of Wilson's disease and Alzheimer's disease, and copper lowering therapy in medicine. Inorg Chim Acta 2012;393:135-41.
39. Sparks DL, Schreurs BG. Trace amounts of copper in water induce ?-amyloid plaques and learning deficits in a rabbit model of Alzheimer's disease. Proc Natl Acad Sci USA 2003;100:11065-9.
40. Sparks DL, Friedland R, Petanceska S, Schreurs BG, Shi J, Perry G, et al. Trace copper levels in the drinking water, but not zinc or aluminum influence CNS Alzheimer-like pathology. J Nutr Health Aging 2006;10:247-54.
41. Morris MC, Evans DA, Tangney CC, Bienias JL, Schneider JA, Wilson RS, et al. Dietary copper and high saturated and trans fat intakes associated with cognitive decline. Arch Neurol 2006;63:1085-8.
42. Loef M, Walach H. Copper and iron in Alzheimer's disease: A systematic review and its dietary implications. Br J Nutr 2012;107:7-19.
43. Eskici G, Axelsen PH. Copper and oxidative stress in the pathogenesis of Alzheimer's disease. Biochemistry 2012;51:6289-311.
44. Buettner GR. Use of ascorbate as a test of catalytic metals in simple buffers. Methods Enzymol 1990;186:125-7.
45. Wolff SP, Jiang ZY, Hunt JV. Protein glycation and oxidative stress in diabetes mellitus and ageing. Free Radic Biol Med 1991;10:339-52.
46. Udenfriend S, Clark CT, Axelrod J, Brodie BB. Ascorbic acid in aromatic hydroxylation. I. A model system for aromatic hydroxylation. J Biol Chem 1954;208:731-39.
47. Brodie BM, Axelrod J, Shore PA, Udenfriend S. Ascorbic acid in aromatic hydroxylation. II. Products formed by reaction of substrates with ascorbic acid, ferrous iron and oxygen. J Biol Chem 1954;208:741-50.
48. Amici A, Levine RL, Tsai L, Stadtman ER. Conversion of amino acid residues in proteins and amino acid homopolymers to carbonyl derivatives by metal-catalyzed oxidation reactions. J Biol Chem 1989;264:3341-6.
49. Refsgaard HH, Tsai L, Stadtman ER. Modifications of proteins by polyunsaturated fatty acid peroxidation products. Proc Natl Acad Sci USA 2000;97:611-6.
50. Stumm W, Lee GF. Oxygenation of ferrous ion. Ind Eng Chem 1961;53:143-6.
51. Howells C, Saar K, Eaton E, Ray S, Palumaa P, Shabala L, et al. Redox-active Cu(II)-Acauses substantial changes in axonal integrity in cultured cortical neurons in an oxidative-stress dependent manner. Exp Neurol 2012;237:499-506.
52. Qian M, Liu M, Eaton JW. Transitions metals bind to glycated proteins forming redox active "glycochelates": implications for the pathogenesis of certain diabetic complications. Biochem Biophys Res Commun 1998;250:385-9.
53. Saxena P, Saxena AK, Cui XL, Obrenovich M, Gudipaty K, Monnier VM. Transition metal-catalyzed oxidation of ascorbate in human cataract extracts. Possible role of advanced glycation end products. Invest Ophthalmol Vis Sci 2000;41:1473-81.
54. Feaga HA, Maduka RC, Foster MN, Szalai VA. Affinity of Cu+ for the copper binding domain of the ?-amyloid peptide of Alzheimer's disease. Inorg Chem 2011;50:1614-8.
55. Huang D, Ou B, Prior RL. The chemistry behind antioxidant capacity assays. J Agric Food Chem 2005;53:1841-56.
56. Apak R, Guclu K, Demirata B, Ozyurek M, Celik SE, Bektasoglu B, et al. Comparative evaluation of various total antioxidant capacity assays applied to phenolic compounds with the CUPRAC assay. Molecules 2007;12:1496-547.
57. McMillin GA, Travis JJ, Hunt JW. Direct measurement of free copper in serum or plasma ultrafiltrate. Clin Chem 2009:131:160-5.
58. Miyata T, Ueda Y, Yamada Y, Izuhara Y, Wada T, Jadoul M, et al. Accumulation of carbonyls accelerates the formation of pentosidine, an advanced glycation end product: carbonyl stress in uremia. J Am Soc Nephrol 1998;9:2349-56.
59. Miyata T, Wada T, Cai Z, Iida Y, Horie K, Yasuda Y, et al.Implication of an increased oxidative stress in the formation of advanced glycation end products in patients with end-stage renal disease. Kidney Int 1997;51:1170-81.
60. Lee KW, Mossine V, Ortwerth BJ. The relative ability of glucose and ascorbate to glycated and crosslink lens proteins in vitro. Exp Eye Res 1998;67:95-104.